Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial

Abstract

The article describes backround and design of mortality/morbidity clinical trial, phase III, RED-HF, studying effects of treatment of patients with chronic heart failure and severe anaemia using erythropoiesis-stimulating agent darbepoetin alfa vs. placebo.

Keywords

• Heart failure
• anaemia
• RED-HF